- Trials with a EudraCT protocol (281)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
281 result(s) found for: Oral contraceptive pill.
Displaying page 1 of 15.
EudraCT Number: 2007-005453-36 | Sponsor Protocol Number: MPC134 | Start Date*: 2009-02-19 | |||||||||||
Sponsor Name:Central and North West London NHS Foundation Trust (Camden Provider Services) | |||||||||||||
Full Title: The Effects of Standard vs. Tailored use of the Combined Oral Contraceptive on Continuation Rates at one year. | |||||||||||||
Medical condition: A randomised controlled trial to find out whether tailored pill use is better than standard pill use by seeing which approach leads to more women staying on the pill for at least one year. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001513-33 | Sponsor Protocol Number: CF111/204 | Start Date*: 2013-06-04 | |||||||||||
Sponsor Name:Laboratorios León Farma S.A. | |||||||||||||
Full Title: Phase II trial to evaluate the maintenance of ovulation inhibition with LF111 (drospirenone 4.0 mg 24/4 regimen) after scheduled 24-hour delays in pill intake. | |||||||||||||
Medical condition: Evaluation of ovulation inhibition with scheduled 24h delay in pill intake in healty young females of child bearing potential. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018590-38 | Sponsor Protocol Number: 70421 | Start Date*: 2010-04-14 | |||||||||||
Sponsor Name:LUMC | |||||||||||||
Full Title: The thrombogenicity of the dienogest/estradiol valerate containing oral contraceptive (Qlaira) | |||||||||||||
Medical condition: We will investigate the thrombogenicity of two different oral contraceptives: dienogest/estradiol valerate (Qlaira) in comparison to levonorgestrel/ethinylestradiol (Microgynon-30) used by healthy ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002396-42 | Sponsor Protocol Number: CF111/302 | Start Date*: 2012-02-09 | |||||||||||
Sponsor Name:Laboratorios León Farma S.A. | |||||||||||||
Full Title: A Pivotal, Multicentre, Double-Blind, Double-Dummy, Randomised Trial on the Contraceptive Efficacy, Tolerability and Safety of LF111 (Drospirenone) Over 9 Cycles in Comparison With Desogestrel 0.07... | |||||||||||||
Medical condition: Oral hormonal contraceptive for women without uncontrolled current diseases between 18-45 years. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) CZ (Completed) AT (Completed) ES (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023215-34 | Sponsor Protocol Number: PSE-HSP-203 | Start Date*: 2010-12-20 | |||||||||||
Sponsor Name:Teva Women`s Health Research | |||||||||||||
Full Title: A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-day Extended Cycle Oral Contraceptive Regimen, Compared to two 28-day Standard Oral Contraceptive Regimen... | |||||||||||||
Medical condition: Healthy women taking contraceptive regimen | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005797-58 | Sponsor Protocol Number: 465 | Start Date*: 2013-04-19 | ||||||||||||||||
Sponsor Name:Kvinnokliniken, Universitetessjukhuset i Linköping, landstinget i Östergötland | ||||||||||||||||||
Full Title: Contraception after gastric bypass - part three How does gastric bypass affect the pharmacocinetics of oral desogestrel? | ||||||||||||||||||
Medical condition: We want to investigate how the pharmacocinetics changes for Cerazette in 14 fertile obese women after, compared to before, bariatric surgery in forms of gastric by pass. Mesures of serum concetrati... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002602-78 | Sponsor Protocol Number: DSG-HSP-201 | Start Date*: 2011-09-21 | |||||||||||
Sponsor Name:Teva Women's Health Research&Development, a division of Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women | |||||||||||||
Medical condition: The impact of an experimental birth control drug on hemostatic parameters (characteristics of the blood) compared to a standard marketed birth control pill in healthy women (contraceptive) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007024-26 | Sponsor Protocol Number: BAY 86-5016/91557 | Start Date*: 2009-04-27 | ||||||||||||||||
Sponsor Name:Bayer Healthcare AG | ||||||||||||||||||
Full Title: A single-center, open-label, crossover, randomized study to investigate the impact of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestogene (material no. 8087... | ||||||||||||||||||
Medical condition: healthy volunteers | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-005234-37 | Sponsor Protocol Number: CF111/304 | Start Date*: 2014-05-28 | |||||||||||
Sponsor Name:Laboratorios León Farma S.A. | |||||||||||||
Full Title: Multicentre, Open-Label Trial to Assess the Safety and Tolerability of LF111 (Drospirenone 4.0 mg) Over 6 Cycles in Female Adolescents, With a 7-Cycle Extension Phase | |||||||||||||
Medical condition: Oral contraception for postmenarcheal female adolescents, with or without intact hymen, aged 14-17 and without uncontrolled concomitant disease. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) NL (Not Authorised) FI (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019902-17 | Sponsor Protocol Number: BAY86-5300/14701 | Start Date*: 2010-12-09 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethi... | |||||||||||||
Medical condition: Contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004677-17 | Sponsor Protocol Number: 141022 | Start Date*: 2016-02-29 | ||||||||||||||||
Sponsor Name:Kvinnokliniken, Universitetssjukhuset i Linköping, Landstinget i Östergötland | ||||||||||||||||||
Full Title: Contraception after gastric bypass - part 4 How does gastric bypass affect the pharmacocinetics of oral levonorgestrel? | ||||||||||||||||||
Medical condition: We want to investigate if the pharmacocinetics of levonorgestrel differs in women who have had bariatric surgery compared to women who have not. Measures of serum concentrations of levonorgestrel w... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000925-30 | Sponsor Protocol Number: 10 | Start Date*: 2013-05-04 | |||||||||||
Sponsor Name:Uppsala University | |||||||||||||
Full Title: How common are mood and sexual side-effects from combined oral contraceptives? | |||||||||||||
Medical condition: Healthy women | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002263-13 | Sponsor Protocol Number: 91548 | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contrace... | |||||||||||||
Medical condition: Reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003002-27 | Sponsor Protocol Number: MIT-Es001-C303 | Start Date*: 2020-10-14 | |||||||||||
Sponsor Name:Estetra SRL | |||||||||||||
Full Title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate an... | |||||||||||||
Medical condition: Contraception | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: FI (Completed) EE (Completed) LV (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014911-11 | Sponsor Protocol Number: BAY86-5300/14567 | Start Date*: 2010-06-18 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A multi-centre, randomized, double-blind, active control, parallel-group, 2-arm study to investigate the effect of ethinylestradiol / drospirenone / (0.02 mg/3 mg) oral contraception in a 24/4 regi... | |||||||||||||
Medical condition: Oral Contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) CZ (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003831-39 | Sponsor Protocol Number: LPRI421-202 | Start Date*: 2017-03-31 | ||||||||||||||||
Sponsor Name:Exeltis France S.A. | ||||||||||||||||||
Full Title: Multicentre, phase II, open label randomised clinical trial to assess the bleeding profile, tolerability and safety associated with the use of three prolonged release formulations containing a comb... | ||||||||||||||||||
Medical condition: Oral contraception for females aged 18-35 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: LT (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003226-42 | Sponsor Protocol Number: 91550 | Start Date*: 2008-12-10 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, active-controlled, parallel group, 2-arm study to investigate the effect of estradiol valerate/dienogest compared to Microgynon on hormone withdrawal associ... | |||||||||||||
Medical condition: Hormone withdrawal associated symptoms of headache and pelvic pain suffered by patients receiving LNG containing oral contraception. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) ES (Completed) GB (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002220-32 | Sponsor Protocol Number: 225/2611 | Start Date*: 2012-06-13 |
Sponsor Name:OYS | ||
Full Title: The effects of contraceptive pill and hormonal vaginal ring on hormonal, inflammatory and metabolic parameters in women of reproductive age with polycystic ovary syndrome (PCOS). | ||
Medical condition: Polycystic Ovary Syndrome (PCOS) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024546-30 | Sponsor Protocol Number: CF111/202 | Start Date*: 2012-02-10 | |||||||||||
Sponsor Name:Laboratories León Farma S.A. | |||||||||||||
Full Title: Randomized, Open-Label Study to Evaluate the Influence on the Ovarian Activity, and the Cervix Score Over Two Treatment Cycles of 4.0 mg Drospirenone Daily for 24 Days as Compared to 0.075 mg Desog... | |||||||||||||
Medical condition: Evaluation of the influence on the ovarian activity, the cervix score, the bleeding pattern and the endometrial thickness in healthy young females. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000790-24 | Sponsor Protocol Number: BEC01 | Start Date*: 2020-07-14 | |||||||||||||||||||||
Sponsor Name:Universität Salzburg | |||||||||||||||||||||||
Full Title: BECONTRA - Effects of combined oral contraceptives on brain and behavior | |||||||||||||||||||||||
Medical condition: Girls and women 14 years - 35 years, considering the intake of COCs or under current use of EE/LNG or EE/CMA COCs | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
